INDIANAPOLIS, Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first time in a late-breaking oral presentation at the San Antonio Breast Cancer Symposium (SABCS) taking place December 10-13 in San Antonio, TX. EMBER-3 is a study in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast can ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . We're just days away from the U.S. General Election, which means tensions are running hot. Both sides of the political aisle seem to make the case that if the other side wins, democracy is lost and the economy is in trouble. Analyst's Disclosure: I/we have a beneficial long pos ...

The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut. High-flying aircraft experience turbulence from time to time. It's the same story with stocks. We saw that happen with Eli Lilly (LLY -2.02%) this week. Lilly announced its third-quarter results on Wednesday. Investors didn't like what they heard. The big pharma stock initially plunged close to 15% after the market opened on Thursday before bouncing back somewhat. Even with this partial rebound, Lilly's share price remains roughl ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and onl ...

Boston, MA - August 13: Sarah Mullins, a scientist at Amplitude Therapeutics, works at the new Lilly ... [+] Seaport Innovation Center, a 12-story 346,000-square-foot building along Fort Point Channel. (Photo by David L. Ryan/The Boston Globe via Getty Images) Boston Globe via Getty Images Eli Lilly stock (NYSE: LLY) fell over 6% on Wednesday, October 30, after it posted downbeat results. The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimat ...

Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024. Eli Lilly (LLY -6.28%) stock tanked after the company reported third-quarter results on Wednesday, Oct. 30. The report it issued before the opening bell was more than a little problematic. In addition to top-line figures that missed Wall Street expectations, management lowered its earnings outlook. If there's one thing the stock market hates, it's unpredictability. Eli Lilly shares were down by m ...

Financial Data and Key Metrics - Revenue grew 42% excluding the impact of the divested olanzapine portfolio, driven by new products like Mounjaro and Zepbound [7] - New product revenue grew by over $3 billion, with U.S. prescription volume growth of 25% in Q3 [7] - Gross margin increased to 82.2%, benefiting from favorable product mix and higher realized prices [16] - Operating income reached nearly $1.8 billion, driven by higher revenue from new products [18] - Earnings per share (EPS) was $1.18, up from $0.10 in Q3 2023, despite a negative impact of $3.08 from acquired IPR&D charges [18] Business Line Performance - Mounjaro sales were $3.1 billion globally, with $2.4 billion in the U.S. and $728 million outside the U.S. [23] - Verzenio sales increased 32% worldwide, driven by strong execution in early breast cancer [23] - Jaypirca revenue was $81 million, showing sustained uptake in MCL and CLL patient populations [24] - Omvoh revenue increased to $41 million, with first-line access at two out of three major PBMs expected by January 2025 [24] - Trulicity revenue declined 22%, driven by lower volume partially offset by higher realized prices [25] Market Performance - U.S. revenue increased 46%, with volume growth of 35% driven by Zepbound and Mounjaro [19] - Europe revenue grew 39% in constant currency, driven by Mounjaro, Verzenio, and Jardiance [21] - Revenue in the rest of the world grew 45% in constant currency, led by Mounjaro [21] - China revenue increased 17% in constant currency, driven by volume growth of Tyvyt and favorable pricing for Humalog [22] - Japan revenue grew 17% in constant currency, with volume growth of 20% driven by Mounjaro, Verzenio, and Jardiance [22] Strategy and Industry Competition - The company invested nearly $2 billion in manufacturing expansion in Ireland, bringing total commitments since 2020 to over $20 billion [11] - A separate $4.5 billion investment was announced for the Lilly Medicine Foundry, focusing on R&D for manufacturing process design [12] - The acquisition of Morphic Therapeutics added oral integrin assets to the early-phase immunology portfolio [13] - The company returned over $1.6 billion to shareholders via dividends and share repurchases [13] Management Commentary on Operating Environment and Future Outlook - The company expects to exceed the production target of at least 1.5 times the saleable doses of incretin medicines in the second half of 2024 compared to the second half of 2023 [8] - Management is confident in the company's future, with a cohort of medicines expected to drive growth through the balance of the decade [63] - The company plans to scale R&D and increase investments in manufacturing and commercial operations to support successful launches in 2025 [63] Other Important Information - The company updated its full-year revenue guidance to $45.4 billion to $46 billion, representing approximately 50% growth in Q4 2024 compared to the same quarter last year [28] - The expected effective tax rate was updated to approximately 17%, driven by the impact of non-deductible IPR&D in Q3 [32] - EPS is now expected to be in the range of $12.05 to $12.55 on a reported basis and $13.02 to $13.52 on a non-GAAP basis [32] Q&A Session Summary Question: Bridge from Q3 sales to Q4 implied results - The company expects a 50% growth in Q4 compared to Q3, driven by accelerated demand generation efforts and improved capacity [66][70] Question: Q3 volatility and demand trends - The company attributed Q3 volatility to channel stocking dynamics and supply constraints, but underlying demand remains strong [72][77] Question: Impact of compounding on demand - The company does not see a significant financial impact from compounding but is concerned about safety and quality issues [79][81] Question: Resolution of compounding crisis with oral small molecules - The company believes oral products like orforglipron could help address the compounding issue in the long term, but it is not a crisis for Lilly [86][88] Question: Access and demand generation for Zepbound - The company has made significant progress in access for Zepbound, with 87% commercial access and ongoing efforts to expand employer opt-ins [91][93] Question: Supply capacity for 2025 - The company expects strong growth in supply capacity for 2025, driven by previous investments in manufacturing [100][102] Question: Inventory dynamics and LillyDirect launch - The launch of LillyDirect self-pay had a limited impact on Q3 sales, but the company expects it to be an important channel for future growth [105][107] Question: DTC for Zepbound and competition - The company is initiating DTC efforts to drive consumer awareness, as unaided awareness for Zepbound remains low [111][115] Question: Peresolimab and PD-1 agonist development - The company discontinued peresolimab due to an unfavorable benefit-risk profile in Phase 2b and does not currently have a follow-on PD-1 agonist in development [118][121] Question: Verzenio market share and IRA impact - The company expects Verzenio to maintain its position in the high-risk adjuvant setting, with Part D reform likely having a neutral impact [123][126] Question: Operating margin trajectory - The company expects operating margin expansion in the short term, with continued investments in SG&A and R&D driving long-term growth [130][134] Question: Pricing evolution for Mounjaro and Zepbound - The company expects stable pricing for Mounjaro and Zepbound, with potential impacts from new indications like obstructive sleep apnea [136][138] Question: Long-term obesity market and orforglipron - The company sees significant potential for orforglipron to expand the obesity market, particularly as an oral option with efficacy comparable to injectables [141][145]

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.1% on Wednesday.The Dow traded up 0.07% to 42,262.68 while the NASDAQ fell 0.05% to 18,703.09. The S&P 500 also fell, dropping, 0.03% to 5,831.09.Check This Out: Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For OctoberLeading and Lagging SectorsCommunication services shares rose by 1.8% on Wednesday.In trading on Wednesday, information technology shares fell by 0.9%.Top HeadlineOn Wednesday, Eli ...

Eli Lilly's stock (NYSE: LLY ) has been duly adjusted this AM following a surprise slash to its full year 2024 guidance. This marks a stark pivot from two consecutive quarters of raised revenue guidance in the billions, driven by continued demand momentum Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not ...

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-thanexpected sales for the third quarter, even as supply of both medicines have largely recovered from widespread shortages in the U.S. The reason, according to the company, is not an issue of demand or supply. Eli Lilly instead blamed disappointing sales on drug wholesalers cutting inventory o ...